Phase 3 Clinical Trials With Primary Completion Dates in February 2022
This is a list of Phase 3 trials with primary completion dates in February 2022 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| ASND | Ascendis Pharma A/S | 2022-02-01 | Phase 3 | NCT04701203 | A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Daily in Adults With Hypoparathyroidism |
| BLUE | bluebird bio, Inc. | 2022-02-01 | Phase 3 | NCT02906202 | A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Subjects With Transfusion-Dependent β-Thalassemia, Who do Not Have a β0/β0 Genotype |
| CLVS | Clovis Oncology, Inc. | 2022-02-01 | Phase 3 | NCT02975934 | A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency |
| CYDY | CytoDyn Inc. | 2022-02-01 | Phase 3 | NCT04901689 | Leronlimab in Patients With Coronavirus Disease 2019 (COVID-19) With Need for Mechanical Ventilation or Extracorporeal Membrane Oxygenation |
| EIGR | Eiger BioPharmaceuticals, Inc. | 2022-02-01 | Phase 3 | NCT04727424 | Repurposed Approved and Under Development Therapies for Patients With Early-Onset COVID-19 and Mild Symptoms |
| NEPH | Nephros, Inc. | 2022-02-01 | Phase 3 | NCT02757872 | Effects of Vitamin D and Fish Oil on the Kidney in Hypertensives |
| SAGE | Sage Therapeutics, Inc. | 2022-02-01 | Phase 3 | NCT03864614 | A Study to Evaluate SAGE-217 in Adult Participants With Major Depressive Disorder (MDD) |